SCHEMBL15969813

SCHEMBL15969813

CC(COc1ccccc1C(F)(F)F)NC(=O)c1c(O)c(=O)[nH]c2ccc(OC(F)(F)F)cc12

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.40
KDM4E B2RXH2 3/20 0.40
MEN1 O00255 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NLRP3 Q96P20 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
CYP2C9 P11712 1/20 0.38
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
TRPV1 Q8NER1 6/20 0.37
PDE2A O00408 2/20 0.36
MCL1 Q07820 1/20 0.35
GAA P10253 1/20 0.35
SERPINE1 P05121 1/20 0.35
STK33 Q9BYT3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15969812 1.00 KMT2A (0.40) KMT2AKDM4EMEN1SMN1; SMN2NLRP3
SCHEMBL15978936 0.89 POLB (0.43) KMT2AKDM4EMEN1SMN1; SMN2NLRP3
SCHEMBL15981228 0.85 CYP2C9 (0.43) KMT2AKDM4EMEN1SMN1; SMN2NLRP3
SCHEMBL15969419 0.85 CYP2C9 (0.43) KMT2AKDM4EMEN1SMN1; SMN2NLRP3
SCHEMBL16645979 0.85 CYP2C9 (0.43) KMT2AKDM4EMEN1SMN1; SMN2NLRP3
SCHEMBL15969669 0.84 CYP2C9 (0.41) KMT2AKDM4EMEN1SMN1; SMN2NLRP3
SCHEMBL15969670 0.84 CYP2C9 (0.41) KMT2AKDM4EMEN1SMN1; SMN2NLRP3
SCHEMBL15969259 0.83 MCL1 (0.42) KMT2AKDM4EMEN1NPC1RAB9A
SCHEMBL15970555 0.75 LIPG (0.44) KMT2AKDM4EMEN1NPC1RAB9A
SCHEMBL15978945 0.72 MCL1 (0.45) KMT2AKDM4EMEN1MCL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760840-B1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP claimed
EP-2760840-B1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP disclosed
US-20150105376-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-04-16 US disclosed
US-8946430-B2 Quinolinone carboxamide inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2015-02-03 US disclosed
US-20140243314-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105376-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, PNLIP, LPL KMT2A 1068/4885KDM4E 483/4885MEN1 4291/4885
US-20140243314-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, PNLIP, LPL KMT2A 1068/4885KDM4E 483/4885MEN1 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.